WINDSOR, ON / ACCESSWIRE / May 6, 2015 /
The Wealthy Biotech Trader, an Investment
Newsletter focused on showing everyday Investors new opportunities
in rapidly growing little-known Biotech stocks, would like to
highlight several oncology (or cancer) focused biotech stocks
providing investors with greatest opportunity for significant
growth potential.
2015 has so far been the year of the biotech company and
investors are presented with a growing list of potential investment
opportunities. Here's a look at four of the companies that have
been stand-out so far this year and present investors with
significant upside opportunity. All have witnessed strong
developments operationally and have experienced a surge in investor
interest.
Propanc Health Group Corporation (OTC: PPCH), a
development stage healthcare company that is currently focused on
developing new cancer treatments for patients suffering from
pancreatic and colorectal cancer, leads a very interesting field of
companies that are making significant progress in the oncology
space.
Propanc recently announced the first set of results from its
animal studies using its treatment called PRP. According to the
company's announcement, PRP is showing no adverse clinical signs at
the maximum tolerated dose (MTD) in mice when administered by I.V
injection. Propanc has concluded that the findings are significant,
showing that PRP is safe and tolerable when administered
intravenously at higher doses. Follow-up to this news should report
on its efficacy, or simply how well PRP works on tumors.
The successful testing of PRP in animals paves the way for the
next step in the process of bringing a safe and effective treatment
solution to market. Indeed human clinical trials are an important
measure for the growth potential of any biotech opportunity and so
far Propanc looks poised to make the next big leap.
Since being featured in the NY Times Sunday Edition Magazine
under Health Essentials: Cancer Prevention & Treatment, April
19th, Propanc has eclipsed both its first and second resistance
levels. Trading at just a shave over 5 cents in a recent session,
the company has shown that investor interest is rising steadily and
confirms that PRP could be an effective treatment solution for
cancer, showing remarkable progress.
Investors should pay close attention to the underlying
infrastructure of Propanc's leading treatments which, for the most
part, are based on the company's novel formulation that either
involve or employ proenzymes - essential clinical components and
inactive precursors of enzymes.
Of course, there are several other players in the oncology space
providing investors with significant growth opportunity. Most
notable is Galena Biopharma, Inc. (GALE), a
company that recently completed enrollment in the NeuVax(TM)
(nelipepimut-S) Phase 3 PRESENT (Prevention of Recurrence in
Early-Stage, Node-Positive Breast Cancer with Low to Intermediate
HER2 Expression with NeuVax Treatment) clinical trial. The news is
significant because NeuVax(TM) is a first-in-class, HER2-directed
cancer immunotherapy which is currently being evaluated for its
efficacy in preventing the recurrence of breast cancer.
Considering that breast cancer is the most frequently diagnosed
cancer in the US for women, progress being made on the ground by
Galena is potentially life-saving news. The company which found
support at $1.37 has once again put itself on the investing radar
courtesy of healthy pullbacks. Currently the stock has a second
resistance point of $1.41 and there's a general belief that the
strong sector news could be a catalyst for a potential
breakout.
Unlike the previously mentioned two biotech companies,
Aeterna Zentaris Inc. (AEZS) is on a more advanced
path clinically. The company recently announced that the
independent Data Safety Monitoring Board (DSMB) for its important
late-stage study on zoptarelin doxorubicin has been given the
go-ahead for the continued phase III clinical study for the
treatment of women suffering from advanced metastatic endometrial
cancer. Again, this development shines the light on the importance
of the continued development of treatment for women affected by a
plethora of cancers. Investors have treated Aeterna Zentaris with
no less optimism and the stock has reached as high as 1.54 in the
last 12 months.
Consolidation for Aeterna Zentaris has been pretty steady over
the last few weeks where the stock has found support at around 54
cents. Incidentally, resistance at the upper level is currently 58
cents which suggests that at current levels investors who take
action could be looking at a potential breakout opportunity.
Finally, investors looking for the best of breed in terms of
biotech upside shouldn't ignore the exploits of Threshold
Pharmaceuticals Inc. (THLD). The developer of Evofosfamide
(previously known as TH-302), an investigational hypoxia-activated
prodrug, has announced intent to initialize phase II clinical
trials for its newly acquired cancer candidate, TH-4000.
Threshold Pharmaceuticals licensed TH-4000 (formerly known as
PR610 or Hypoxin) from the University of Auckland of New Zealand
back in September 2014. The drug holds promise because when it
enters the tumor cells, it diffuses to the hypoxic zone, in which
the TH-4000 effector (TH-4000E) is selectively activated and blocks
hypoxia-induced EGFR signaling and tumor cell survival. In a very
basic sense, TH-4000 is able to help in combatting the survival of
cancer-protracting EGFR.
Threshold Pharmaceuticals has enjoyed very strong consolidation
below 4.00 but investors have enjoyed rallies as high as 5.41 in
the last year. The stock is trading just above support of 3.42 and
with resistance not very far north at 3.74, investors could be in
line for another major delivery of profits on a potential
breakout.
The biotech industry presents incredible growth potential for
investors savvy enough to seize the opportunity today. Companies
like Propanc Health Group Corporation (PPCH) are
solid growth candidates as they combine the best of both worlds -
solid fundamentals and very robust technicals.
The Wealthy Biotech Trader is researching several new trade
ideas which have the makings for large market moves. Active traders
are urged to follow our parent outlet, The Wealthy Venture
Capitalist on social media to stay
apprised. We are an anti-email media outlet, and
as such will only be releasing our reports/ updates/ news through
our Twitter and Facebook accounts, as well as newswire.
TO GET BREAKING NEWS FROM US:
Add us on twitter: @Wealthy_VC
Like us on Facebook:
www.facebook.com/groups/TheWealthyVentureCapitalist/
FOR FURTHER INFORMATION PLEASE CONTACT US
AT:
Email: TheWealthyVentureCapitalist@Gmail.com
This report/release/profile is a commercial
advertisement and is for general information purposes only. We are
engaged in the business of marketing and advertising companies for
monetary compensation unless otherwise stated below.
The Wealthy Biotech Trader and its employees are not a
Registered Investment Advisors, Broker Dealers or a member of any
association for other research providers in any jurisdiction
whatsoever and we are not qualified to give financial advice.
The information contained herein is based on sources which we
believe to be reliable but is not guaranteed by us as being
accurate and does not purport to be a complete statement or summary
of the available data. The Wealthy Biotech Trader encourages
readers and investors to supplement the information in these
reports with independent research and other professional advice.
All information on featured companies is provided by the companies
profiled through their website, news releases, and corporate
filings, or is available from public sources and The Wealthy
Biotech Trader makes no representations, warranties or guarantees
as to the accuracy or completeness of the disclosure by the
profiled companies. Further, The Wealthy Biotech Trader has no
advance knowledge of any future events of the profiled companies
which includes, but is not limited to, news & press releases,
changes in corporate structure, or changes in share structure.
Our website and newsletter are for Entertainment purposes only.
This newsletter is NOT a source of unbiased information. Never
invest in any stock featured on our site or emails unless you can
afford to lose your entire investment.
Release of Liability: Through use of this email and/or website
advertisement viewing or using you agree to hold The Wealthy
Biotech Trader, its operators owners and employees harmless and to
completely release them from any and all liability due to any and
all loss (monetary or otherwise), damage (monetary or otherwise),
or injury (monetary or otherwise) that you may incur. The Wealthy
Biotech Trader sponsored advertisements do not purport to provide
an analysis of any company's financial position, operations or
prospects and this is not to be construed as a recommendation by
The Wealthy Biotech Trader or an offer or solicitation to buy or
sell any security.
COMPENSATION: The Wealthy Biotech Trader's
parent company has been compensated ten thousand dollars cash via
bank wire by Propanc Health Group Inc. (OTC: PPCH)
for an Investor Relations Contract and the Company will continue
these services in the future for roughly $5,000 per month. The
Wealthy Biotech Trader's owner / controlling parent entity has also
been compensated $60,000 by the Company in the form of a
convertible note and readers should understand they will convert
this note into common shares and sell them into the market as soon
as the statutory 144 hold period has lapsed. This compensation
constitutes a conflict of interest as to our ability to remain
objective in our communication regarding the profiled company.
None of the materials or advertisements herein constitute offers
or solicitations to purchase or sell securities of the companies
profiled herein and any decision to invest in any such company or
other financial decisions should not be made based upon the
information provide herein. Instead The Wealthy Biotech Trader
strongly urges you conduct a complete and independent investigation
of the respective companies and consideration of all pertinent
risks. Readers are advised to review SEC periodic reports: Forms
10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.
The Wealthy Biotech Trader further urges you to consult your own
independent tax, business, financial and investment advisors.
Investing in micro-cap and growth securities is highly speculative
and carries and extremely high degree of risk. It is possible that
an investor's investment may be lost or impaired due to the
speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides
investors a 'safe harbor' in regard to forward-looking statements.
Any statements that express or involve discussions with respect to
predictions, expectations, beliefs, plans, projections, objectives,
goals, assumptions or future events or performance are not
statements of historical fact may be "forward looking statements".
Forward looking statements are based on expectations, estimates,
and projections at the time the statements are made that involve a
number of risks and uncertainties which could cause actual results
or events to differ materially from those presently anticipated.
Forward looking statements in this action may be identified through
use of words such as "projects," "foresee," "expects," "will, "
"anticipates," "estimates," "believes," "understands," or that by
statements indicating certain actions "may," "could," or "might"
occur. Understand there is no guarantee past performance will be
indicative of future results. Past Performance is based on the
security's previous day closing price and the high of day price
during our promotional coverage.
The Wealthy Venture Capitalist is a media, marketing and
advertising outlet which consists of several sector-focused outlets
collectively referred to as the Wealth Series: The Wealthy Biotech
Trader, The Silicon Valley Insider and the Radical Consumerist
(other may be added in the future). All of these outlets are named
as "pen names" for the parent Company that owns and controls them,
Circadian Group.
In preparing this publication, The Wealthy Biotech Trader has
relied upon information supplied by various public sources and
press releases which it believes to be reliable; however, such
reliability cannot be guaranteed. Investors should not rely on the
information contained in this email and website. Rather, investors
should use the information contained in this website as a starting
point for doing additional independent research on the featured
companies. The advertisements in this email and website are
believed to be reliable, however, The Wealthy Biotech Trader and
its owners, affiliates, subsidiaries, officers, directors,
representatives and agents disclaim any liability as to the
completeness or accuracy of the information contained in any
advertisement and for any omissions of materials facts from such
advertisement. The Wealthy Biotech Trader is not responsible for
any claims made by the companies advertised herein, nor is The
Wealthy Biotech Trader responsible for any other promotional firm,
its program or its structure.
SOURCE: The Wealthy Biotech Trader
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Apr 2023 to Apr 2024
